CUSTOM DERMATOLOGY SEARCH:
Finasteride for Male Pattern Hair Loss
Hair loss has a significant psychosocial effect on some men. In these men, safe and effective treatment of hair loss is important to quality of life.2
Efficacy of finasteride1
Efficacy has been demonstrated in three double-blind, randomized, placebo-controlled studies in 1,879 men between 18–41 years of age with mild to moderate androgenetic alopecia. Two of the studies enrolled men with mild to moderate vertex loss, the third investigated mild to moderate loss in the anterior mid-scalp area with or without vertex balding. Primary end-points were hair count (assessed by photographic enlargements of a representative area of active hair loss) and patient selfassessment; secondary end-points were investigator assessment and ratings of global photography.
Adverse effects are minimal. Results in men treated with finasteride for benign prostatic hyperplasia, where five times the dose has been studied in men for up to 6 years, have revealed no long-term problems or new effects over the longer period. In patients with AGA treated with 1 mg of finasteride daily for 12 months in controlled studies, 1.4% of finasteride treated patients versus 1.6% of placebo treated patients discontinued therapy because of adverse drug experiences, and 1.2% of finasteride treated patients versus 0.9% of placebo treated patients discontinued because of drug-related sexual experiences. Sexually related adverse effects reported as possibly, probably or definitely drug or placebo related were decreased libido, erectile dysfunction and ejaculation disorder. Analysis showed that 4% of 945 men treated with finasteride and 2% of 934 men treated with placebo reported one or more of these adverse effects (p= 0.04). These problems resolved in all men who stopped therapy with finasteride because of these effects, and in 58% of those who continued therapy.1
Finasteride is not indicated for use in women.1
Pregnancy Use of finasteride is contraindicated in women when they are pregnant or potentially may be pregnant, because of the risk to a male fetus.1
Liver function abnormalities Finasteride is metabolized extensively in the liver and caution should be used when treating patients with liver function abnormalities.
The bioavailability of finasteride is not affected by food. Following oral dosage of finasteride, a mean of 39% (almost entirely as metabolites) is excreted in the urine and 57% in the feces. The metabolites in the urine possess no more than 20% of the 5α-reductase inhibitory activity of finasteride.3 At steady state, the mean terminal half-life of elimination is approximately 5–6 hours in men 18–60 years of age, increasing to 8 hours in men more than 70 years of age. No dosage adjustment is necessary in the elderly or in patients with renal insufficiency.1
No drug interactions of clinical importance have been identified. Finasteride does not appear to affect the cytochrome P450-linked drug metabolizing system.1
Mechanism of action
It is thought that finasteride interrupts a key step in the pathogenesis of AGA, in those patients who are genetically predisposed. Finasteride is a preferential, competitive inhibitor of the intracellular, Type II, 5α-reductase isoenzyme which converts testosterone into dihydrotestosterone (DHT), a more potent androgen. In humans, the Type II 5α-reductase isoenzyme is primarily found in the root sheath of the hair follicle, prostate, seminal vesicles, epididymis, fetal genital skin and in fibroblasts from normal adult genital skin1,3, as well as liver, and is responsible for two-thirds of circulating DHT. In target organs, finasteride treatment is thought to result in selective androgen deprivation affecting DHT without lowering circulating levels of testosterone, thus preserving the desired androgen mediated effects on muscle strength, bone density and sexual function.4 In AGA, the balding scalp contains miniaturized hair follicles and increased amounts of DHT compared with non balding scalp, and finasteride treatment produces inhibition of the isoenzyme, resulting in a rapid reduction in scalp and serum DHT concentrations.1
Dosage and administration
The recommended dosage is one mg once a day. Because of the psychosocial impact of hair loss, it is important to explain what the patient may expect in terms of continuing hair loss. The response to any therapy may be slow and may include hair regrowth and/or retardation of further thinning. 5,6 In general, daily use for at least three months or more is necessary before benefit is observed. Continued use is recommended to sustain benefit as withdrawal of treatment leads to reversal of effect within 12 months.1
There has been some controversy in newspapers and on the Internet about the cost of 1mg tablets of Propecia® compared to the cost of 5mg tablets of Proscar.® The New York Times on January 20th, 1998 used the heading, “New Baldness Drug Is Older Product at a Premium Price” and highlighted the statement that “A prostate treatment grows in value when it grows hair.” Some price difference is reasonable, as Merck has had to finance development and clinical trials for this new indication and their costs must amount to at least tens of millions of dollars. While some user groups have been advocating splitting the 5 mg tablets, there is no data on the stability of tablet fragments, or the efficacy of this approach as Proscar® tablets have only been approved for the treatment of benign prostatic hyperplasia.
Finasteride may hold promise for other DHT-mediated disorders such as facial hirsutism and frontal alopecia.9 Several companies are developing combination Type I and Type II 5α-reductase inhibitors which may be regarded as candidates for treatment of androgen-dependent skin disorders such as seborrhea, acne, hirsutism and/or androgenetic alopecia.9
The place of finasteride in therapy
A recent review in the Medical Letter™ concluded that finasteride can produce a modest increase in hair on the scalps of young men with mild-to-moderate hair loss.7 They also note that treatment must be continued indefinitely to maintain the effect.7
Drug Treatments Introduced in 1997
In this issue:
All content ©2004-2014 SkinTherapyLetter® |
Last modified: Wednesday, 06-Aug-2014 12:41:43 MDT